AstraZeneca Results Presentation Deck
Full year and Q4 2021: key updates
Continuing to deliver on our strategic objectives
Robust growth
Exceeded FY 2021 revenue guidance
Total Revenue $37.4bn (+38%)
$33.4bn (+23%)
excluding FY 2021 Vaxzevria¹ revenue
-
- $35.2bn (+30%)
including Q4 2021 Vaxzevria¹ revenue
• Core EPS $5.29 (+37%)
●
Broad-based performance
Delivering value to patients
Oncology $13.7bn (+17%)
BioPharmaceuticals:
CVRM $8.0bn (+9%)
Respiratory & Immunology
$6.0bn (+9%)
Other medicines $2.5bn (-7%)
COVID-19 $4.1bn (n/m)
• Rare Disease² $3.1bn (+9%)
Science-led innovation
Strong Q4 2021 performance
Tezspire US approval
- severe asthma
Evusheld US EUA
- COVID-19 prophylaxis
Lynparza US Priority Review
- adjuvant breast cancer
Saphnelo EU CHMP recommendation
- systemic lupus erythematosus
• Ultomiris US Priority Review
- generalised myasthenia gravis
FY 2021: Total Revenue $37.4bn (+38%) | Core EPS of $5.29 (+37%)
Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) December 2021, unless stated otherwise. CVRM = Cardiovascular, Renal and Metabolism; COVID-19 = coronavirus
disease 2019; CHMP = Committee for Medicinal Products for Human Use; EUA = Emergency Use Authorisation; n/m = growth rate not meaningful. 1. Vaxzevria Total Revenue' also includes Collaboration Revenue from sub-licensees
6 that produce and supply the AstraZeneca COVID-19 Vaccine under their own trademarks. 2. FY 2021 revenues from date of acquisition closing, 21 July 2021 through 31 December 2021; pro forma growth rates calculated by
comparison post-acquisition revenues with the corresponding prior year revenues adjusted pro-rata to match the post-acquisition period.View entire presentation